HNGZY (Hangzhou Tigermed Consulting Co) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HNGZY Hangzhou Tigermed Consulting Co Ltd HNGZY
89 GF Score
Price $4.45
GF Value $4.87
! 6 Warning Signs
View Full Analysis

What is Hangzhou Tigermed Consulting Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Hangzhou Tigermed Consulting Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $61 Mil. Hangzhou Tigermed Consulting Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $285 Mil. Hangzhou Tigermed Consulting Co's annualized EBITDA for the quarter that ended in Jun. 2026 was $-233 Mil. Hangzhou Tigermed Consulting Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was -1.48.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Hangzhou Tigermed Consulting Co's Debt-to-EBITDA or its related term are showing as below:

HNGZY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.16   Med: 0.94   Max: 4.27
Current: 4.27

During the past 13 years, the highest Debt-to-EBITDA Ratio of Hangzhou Tigermed Consulting Co was 4.27. The lowest was 0.16. And the median was 0.94.

HNGZY's Debt-to-EBITDA is ranked worse than
71.19% of 118 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.475 vs HNGZY: 4.27

Hangzhou Tigermed Consulting Co  (OTCPK:HNGZY) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Hangzhou Tigermed Consulting Co Debt-to-EBITDA Related Terms

Hangzhou Tigermed Consulting Co Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Hangzhou Tigermed Consulting Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hangzhou Tigermed Consulting Co Debt-to-EBITDA Chart

Hangzhou Tigermed Consulting Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hangzhou Tigermed Consulting Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

HNGZY vs TMO, DHR, NTRA: Debt-to-EBITDA Comparison

For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hangzhou Tigermed Consulting Co Debt-to-EBITDA vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Hangzhou Tigermed Consulting Co's Debt-to-EBITDA falls into.


HNGZY
89GF Score
Hangzhou Tigermed Consulting Co Ltd HNGZY
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hangzhou Tigermed Consulting Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Hangzhou Tigermed Consulting Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(102.80768364445 + 137.89788054206) / 176.98704469228
=1.36

Hangzhou Tigermed Consulting Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(60.91260364459 + 284.98365914021) / -233.35430048262
=-1.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Hangzhou Tigermed Consulting Co (HNGZY) Overvalued in 2026?

Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co stock appears to be undervalued. The current stock price of $4.45 is trading 8.6% below its estimated GF Value™ of $4.87.

Key valuation signals for HNGZY:

  • Debt-to-EBITDA:
  • GF Value™: $4.87 vs. price of $4.45 (8.6% below fair value)
  • GF Score™: 89/100 with 6 warning signs

No single metric tells the full story. See the HNGZY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hangzhou Tigermed Consulting Co Business Description

Address No. 508 Lujiatan Street, Room 601-610, 6th Floor, Puyan Sub-District, Binjiang District, Zhejiang Province, Hangzhou, CHN
Hangzhou Tigermed Consulting Co Ltd is a China-based provider of comprehensive biopharmaceutical R&D services, with an expanding world-wide presence. The Group is principally engaged in CRO services.
89GF Score

Get the complete analysis for HNGZY

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.45
Price
$4.87
GF Value